Article
Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting - 1 Apr 2022
Hasanov Elshad, Pimentel Isabel, Cruellas Mara, Lewis Mark A, Jonasch Eric, Balmaña Judith
Abstract excerpt
Advances in the genetic basis of different tumors have led to identification of tumor vulnerabilities that can be turn into targeted therapies. In this regard, PARP inhibitors cause synthetic lethality with tumors harboring BRCA1 or BRCA2 genetic alterations. On the other hand, tumors with microsatellite instability, either due to germline or sporadic alterations, are candidates for immune checkpoint inhibitors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.